The stock seems to be gaining momentum again after a few months of uncharacteristic volatility. Despite being a bit subdued during the last few months, the stock has appreciated by 38% over last one year. The company has been in the news for its deal with Inovio (INO), a smaller company in biotech space. An article on Motley fool mentioned Roche as a good stock for conservative growth for those looking to invest in this sector. The first half of 2013 was reasonably good with 5% increase in revenues and 12% increase in core EPS. The HER2 franchise showed 11% growth, and now accounts for 14% of the company's sales. Working with experimental companies like Inovio (INO) can help Roche prepare for the patent expirations which are starting next year. Hercepting ($6.3 billion in sales in fiscal 2012) is likely to face generic competition next year, but is expected to make up for the loss partly due to the new subcutaneous formulation recently approved in the EU. The Inovio deal is expected to be good for the company in the long term as it gives it exposure to the prostate cancer market. In addition, Inovio's Hepatitis B vaccine is also believed to have a lot of potential. It also gives it access to the electroporation technology for drug delivery. The technology is believed to have a lot of potential, though it has to go through a lot of trials etc. Another technology QuSomes from Biozone (BZNE), which is for liposomal delivery of drugs, is also believed to have a lot of potential for increasing the efficiency and efficacy of delivery of drugs. OPKO Health (OPK) is testing the Qusomes technology for various drugs based on a license agreement with Biozone. Ultimately, once these techniques go past the trial stage, they are likely to reduce the cost of production and the therapy. Roche is perhaps attempting to access these advantages by looking at the smaller players.